The intrinsic transcriptional estrogenic activity of a non-phenolic derivative of levonorgestrel is mediated via the estrogen receptor-α

Journal of Steroid Biochemistry and Molecular Biology

Volumn 82, Issue 4-5, 2002, Pages 333-341

  García Becerra, Rocio ^a   Borja Cacho, Elizabeth ^a   Cooney, Austin J ^b   Jackson, Kathy J ^b   Lemus, Ana E ^c   Pérez Palacios, Gregorio ^d   Larrea, Fernando ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Estrogen effects; Estrogen receptors; Levonorgestrel; Synthetic progestins; Transcription regulation

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LEVONORGESTREL; NANDROLONE; PHENOL; PROGESTERONE;

ARTICLE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HELA CELL; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; MOLECULAR BIOLOGY; PROTEIN ANALYSIS; TRANSACTIVATION;

BACTERIAL PROTEINS; CONTRACEPTIVE AGENTS, FEMALE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; LEVONORGESTREL; PLASMIDS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SERINE ENDOPEPTIDASES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0036878141     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00192-9     Document Type: Article

References (35)

1. Larrea F., Escobar N., Garza-Flores J., Moctezuma O., Martínez-Campos A., Pérez-Palacios G. Nuclear translocation of estradiol receptors by the in vivo administration of norethisterone: an alternate mechanism of gonadotropin inhibition. J. Steroid Biochem. Mol. Biol. 19:1983;1747-1752.
2. Larrea F., Moctezuma O., Pérez-Palacios G. Estrogen-like effects of norethisterone on the hypothalamic pituitary unit of ovariectomized rats. J. Steroid Biochem. Mol. Biol. 20:1984;841-847.
3. Jeng M.H., Parker C.J., Jordan V.C. Estrogenic potential of progestins in oral contraceptives to stimulate breast cancer cell proliferation. Cancer Res. 52:1992;6539-6546.
4. Pérez-Palacios G., Cerbón M.A., Pasapera A.M., Castro J.I., Enriquez J., Vilchis F., García G.A., Moralí G., Lemus A.E. Mechanisms of hormonal and antihormonal action of contraceptive progestins at the molecular level. J. Steroid Biochem. Mol. Biol. 41:1992;479-485.
5. Markiewicz I., Hochberg R.B., Gurpide E. Intrinsic estrogenicity of some progestagenic drugs. J. Steroid Biochem. Mol. Biol. 41:1992;53-58.
6. Lemus A.E., Vilchis F., Damsky R., Chávez B.A., García G.A., Grillasca I., Pérez-Palacios G. Mechanism of action of levonorgestrel: in vitro metabolism and specific interactions with steroid receptors in target organs. J. Steroid Biochem. Mol. Biol. 41:1992;881-890.
7. Lemus A.E., Santillan R., Damian-Matsumura P., García G.A., Grillasca I., Pérez-Palacios G. In vitro metabolism of gestodene in target organs: formation of A-ring reduced derivatives with oestrogenic activity. Eur. J. Pharmacol. 417:2001;249-256.
8. Braselton W.E., Lin T.J., Ellegood J.O., Mills T.M., Mahesh V.B. Accumulation of norethisterone and individual metabolites in human plasma during short- and long-term administration of contraceptive dosage. Am. J. Obstet. Gynecol. 133:1979;154-160.
9. Verhoven C.H., Krebbers S.F., Wagenaars G.N., Vos R.M. In vitro and in vivo metabolism of desogestrel in several species. Drug Metab. Dispos. 26:1998;927-936.
10. Larrea F., Vilchis F., Chávez B., Pérez A.E., Garza-Flores J., Pérez-Palacios G. The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J. Steroid Biochem. Mol. Biol. 27:1987;657-663.
11. Garza-Flores J., Menjivar M., Cárdenas M., Reynoso M., García G.A., Pérez-Palacios G. Further studies on the antigonadotropic mechanism of action of norethisterone. J. Steroid Biochem. Mol. Biol. 38:1991;89-93.
12. Lemus A.E., Enriquez J., García G.A., Grillasca I., Pérez-Palacios G. 5α-Reduction of norethisterone enhances its binding affinity for androgen receptor but diminishes its androgenic potency. J. Steroid Biochem. Mol. Biol. 60:1997;121-129.
13. Lemus A.E., Zaga V., Santillan R., García G.A., Grillasca I., Damian-Matsumura P., Jackson K.J., Cooney A.J., Larrea F., Pérez-Palacios G. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J. Endocrinol. 165:2000;693-702.
14. Moralí G., Lemus A.E., Oropeza M.V., García G.A., Pérez-Palacios G. Induction of sexual behavior by norethisterone: role of its A-ring reduced metabolites. Pharmacol. Biochem. Behav. 37:1990;477-484.
15. Pasqualini J.R., Paris J., Sitruk-Ware R., Chetrite G., Botella J. Progestins and breast cancer. J. Steroid Biochem. Mol. Biol. 65:1998;225-235.
16. Catherino W.H., Jeng M.H., Jordan V.C. Norgestrel and gestodene stimulate breast cancer cell growth through an estrogen receptor mediated mechanism. Br. J. Cancer. 67:1993;945-952.
17. Botella J., Duranti E., Viader V., Duc I., Delansorne R., Paris J. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19 nor-testosterone derivatives on endometrial Ishikawa cells. J. Steroid Biochem. Mol. Biol. 55:1995;77-84.
18. Chávez B.A., Vilchis F., Pérez A.E., García G.A., Grillasca I., Pérez-Palacios G. Stereospecificity of the intracellular binding of norethisterone and its A-ring reduced metabolites. J. Steroid Biochem. Mol. Biol. 22:1985;121-126.
19. Larrea F., García-Becerra R., Lemus A.E., García G.A., Pérez-Palacios G., Jackson K.J., Coleman K.M., Dace R., Smith C.L., Cooney A.J. A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ERα Endocrinology. 142:2001;3791-3799.
20. Vilchis F., Chávez B., Pérez A.E., García G.A., Angeles A., Pérez-Palacios G. Evidence that a non-aromatizable metabolite of norethisterone induces estrogen-dependent pituitary progestin receptors. J. Steroid Biochem. 24:1986;525-531.
21. Smith C.L., Conneely O.M., O'Malley B.W. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6120-6124.
22. Burbach J.P.H., Lopez da Silva S., Cox J.J., Adan R.A.H., Cooney A.J., Tsai M.-J., Tsai S.Y. Repression of estrogen-dependent stimulation of the oxytocin gene by chicken ovalbumin upstream promoter transcription factor I. J. Biol. Chem. 269:1994;15046-15053.
23. Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11:1997;657-666.
24. Cooney A.J., Leng X., Tsai S.Y., O'Malley B.W., Tsai M.-J. Multiple mechanisms of COUP-TF-dependent repression of VDR, TR and RAR transactivation. J. Biol. Chem. 268:1993;4152-4160.
25. Seed B., Sheen J.Y. A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene. 67:1988;271-277.
26. Kuiper G.J.M., Carlsson B.O., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.-Å. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology. 138:1997;863-870.
27. Kuiper G.J.M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5925-5930.
28. Cowley S.M., Hoare S., Mosselman S., Parker M.G. Estrogen receptors α and β form heterodimers on DNA. J. Biol. Chem. 272:1997;19858-19862.
29. Pace P., Taylor J., Suntharalingam S., Coombes R.C., Ali S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α J. Biol. Chem. 272:1997;25832-25838.
30. Tremblay A., Tremblay G.B., Labrie F., Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell. 3:1999;513-519.
31. Delaunay F., Pettersson K., Tujague M., Gustafsson J.-Å. Functional differences between the amino-terminal domains of estrogen receptors α and β Mol. Pharmacol. 58:2000;584-590.
32. Watanbe T., Inoue S., Ogawa S., Ishii Y., Hiroi H., Ikeda K., Orimo A., Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors α and β Biochem. Biophys. Res. Commun. 236:1997;140-145.
33. Santillan R., Pérez-Palacios G., Reyes M., Damian-Matsumura P., García G.A., Grillasca I., Lemus A.E. Assessment of the oestrogenic activity of the contraceptive progestin levonorgestrel and its non-phenolic metabolites. Eur. J. Pharmacol. 427:2001;167-174.
34. Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 51:1996;188-215.
35. Tong W., Perkins R., Xing L., Welsh W.J., Sheehan D.M. QSAR models for binding of estrogenic compounds to estrogen receptor α and β subtypes. Endocrinology. 138:1997;4022-4025.